Trial Profile
A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 01 Jul 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 08 Apr 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.